Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2021-02-11 Sale |
2021-02-16 5:49 pm |
Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer |
1,000 | $64.84 | $64,841 | 102,211 (Direct) |
View |
| 2021-02-11 Sale |
2021-02-16 5:47 pm |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
5,300 | $64.91 | $344,017 | 173,596 (Direct) |
View |
| 2020-11-17 Purchase |
2020-11-19 4:40 pm |
Keros Therapeutics Inc. | KROS | Nussbaum Ran Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. Director 10% Owner |
60,000 | $50 | $3,000,000 | 155,262 (Indirect) |
View |
| 2020-11-17 Purchase |
2020-11-19 4:39 pm |
Keros Therapeutics Inc. | KROS | Kariv Tomer Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. Director 10% Owner |
60,000 | $50 | $3,000,000 | 155,262 (Indirect) |
View |
| 2020-11-17 Purchase |
2020-11-19 4:38 pm |
Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner |
60,000 | $50 | $3,000,000 | 155,262 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2021-02-11 Exercise |
2021-02-16 5:49 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer |
1,000 | $0.48 | 102,211 (Direct) |
View |
| 2021-02-11 Exercise |
2021-02-16 5:49 pm |
N/A 2029-09-18 |
Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer |
1,000 | $0 | 102,211 (Direct) |
View |
| 2021-02-11 Exercise |
2021-02-16 5:47 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
5,300 | $0.3 | 173,596 (Direct) |
View |
| 2021-02-11 Exercise |
2021-02-16 5:47 pm |
N/A 2028-03-25 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
5,300 | $0 | 173,596 (Direct) |
View |
| 2021-01-10 Option Award |
2021-01-12 5:25 pm |
N/A 2031-01-09 |
Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer |
49,150 | $0 | 49,150 (Direct) |
View |
| 2021-01-10 Option Award |
2021-01-12 5:23 pm |
N/A 2031-01-09 |
Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer |
42,250 | $0 | 42,250 (Direct) |
View |
| 2021-01-10 Option Award |
2021-01-12 5:21 pm |
N/A 2031-01-09 |
Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer |
42,250 | $0 | 42,250 (Direct) |
View |
| 2021-01-10 Option Award |
2021-01-12 5:20 pm |
N/A 2031-01-09 |
Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer |
127,200 | $0 | 127,200 (Direct) |
View |
| 2020-12-17 Option Award |
2020-12-21 4:43 pm |
N/A 2030-12-16 |
Keros Therapeutics Inc. | KROS | GRAY MARY ANN Director |
16,587 | $0 | 16,587 (Direct) |
View |